[HTML][HTML] Tumor-associated neutrophils in cancer: going pro
The progression of cancer is not only about the tumor cell itself, but also about other
involved players including cancer cell recruited immune cells, their released pro …
involved players including cancer cell recruited immune cells, their released pro …
[HTML][HTML] Neutrophils in cancer: prognostic role and therapeutic strategies
Expression of high levels of immune cells including neutrophils has been associated with
detrimental outcome in several solid tumors and new strategies to decrease their presence …
detrimental outcome in several solid tumors and new strategies to decrease their presence …
[HTML][HTML] Targeting myeloid chemotaxis to reverse prostate cancer therapy resistance
Inflammation is a hallmark of cancer. In patients with cancer, peripheral blood myeloid
expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter …
expansion, indicated by a high neutrophil-to-lymphocyte ratio, associates with shorter …
Prostate carcinogenesis: inflammatory storms
Prostate cancer is a major cause of cancer morbidity and mortality. Intra-prostatic
inflammation is a risk factor for prostate carcinogenesis, with diet, chemical injury and an …
inflammation is a risk factor for prostate carcinogenesis, with diet, chemical injury and an …
Current treatment strategies for advanced prostate cancer
K Komura, CJ Sweeney, T Inamoto… - … Journal of Urology, 2018 - Wiley Online Library
During the past decade, treatment strategies for patients with advanced prostate cancer
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …
involving stage IV (T4N0M0, N1M0 or M1) hormone‐sensitive prostate cancer and recurrent …
The Akt/mTOR and MNK/eIF4E pathways rewire the prostate cancer translatome to secrete HGF, SPP1 and BGN and recruit suppressive myeloid cells
D Brina, A Ponzoni, M Troiani, B Calì, E Pasquini… - Nature Cancer, 2023 - nature.com
Cancer is highly infiltrated by myeloid-derived suppressor cells (MDSCs). Currently
available immunotherapies do not completely eradicate MDSCs. Through a genome-wide …
available immunotherapies do not completely eradicate MDSCs. Through a genome-wide …
Treating patients with metastatic castration resistant prostate cancer: a comprehensive review of available therapies
ED Crawford, CS Higano, ND Shore… - The Journal of …, 2015 - auajournals.org
Purpose: The availability of newly approved treatment options for metastatic castration
resistant prostate cancer is not matched with conclusive data on optimal sequencing …
resistant prostate cancer is not matched with conclusive data on optimal sequencing …
[HTML][HTML] Baseline neutrophil–lymphocyte ratio (NLR) is associated with survival and response to treatment with second-line chemotherapy for advanced prostate …
We investigated the value of the neutrophil–lymphocyte ratio (NLR) in patients with CRPC
treated with chemotherapy in the phase III TROPIC trial. High NLR was associated with …
treated with chemotherapy in the phase III TROPIC trial. High NLR was associated with …
[HTML][HTML] Systemic immune-inflammation index predicts the clinical outcome in patients with mCRPC treated with abiraterone
C Lolli, O Caffo, E Scarpi, M Aieta… - Frontiers in …, 2016 - frontiersin.org
Background: A systemic immune-inflammation index (SII) based on neutrophil (N),
lymphocyte (L), and platelet (P) counts has shown a prognostic impact in several solid …
lymphocyte (L), and platelet (P) counts has shown a prognostic impact in several solid …
Sequencing of agents in castration-resistant prostate cancer
Until 2010, docetaxel was the only agent with proven survival benefit for castration-resistant
prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium …
prostate cancer. The development of cabazitaxel, abiraterone acetate, enzalutamide, radium …